Indomo is building the first at-home, self-injectable prescription therapy for inflammatory acne — pairing a proprietary microneedle self-injection pen (the ClearPen) with a modernized formulation of triamcinolone acetonide, an AAD first-line corticosteroid backed by 50+ years of clinical use. The wedge is a drug/device combination that converts what has historically been an in-office dermatologist procedure into a reimbursable at-home intervention. That pivot — executed in March 2024 when Cedar declined to grant the drug-side FDA pass and Rick reoriented from a D2C aesthetic launch toward a life-sciences combo product — unlocked a $300–600M annual US reimbursement pool and re-framed the exit surface from consumer M&A to pharma M&A.
Validation is decisive. After a flat Series A in which StoryHouse purchased 2,560,819 new Series A-1 shares and its CV converted to 2,648,939 (5,209,758 total shares), Indomo closed a $22M Series B at a $75M post in 2025 — split across a $15M tranche on $35M pre and a $7M tranche on $68M pre — with Foresite Capital leading at $12M alongside Polaris Partners and Atomic. StoryHouse's original $200K Seed II check into the $10M round at $25M post is now marked to $75M — a 3.0x paper markup. DT-001 is anticipated to advance into Phase 2 trials in 2026 and Lifecore Biomedical signed a CDMO agreement in March 2026 to support the corticosteroid formulation.
Injectable drug delivery is a $256B market growing to $373B by 2030 at 7.8% CAGR, with the homecare sub-segment accelerating at 9.2% as chronic-condition management shifts out of the clinic. Indomo's specific wedge — reimbursable at-home intralesional corticosteroid injection — sits inside the AAD first-line acne guideline and taps a $300–600M US annual payor pool per the 2024-03-07 Rick call.
| Player | Positioning | Funding | Edge |
|---|---|---|---|
| Indomo (ClearPen + DT-001) | At-home self-injection microneedle + modernized triamcinolone acetonide for inflammatory acne lesions | Series B $22M on $75M post (2025); $16M raised pre-B | — |
| AviClear (Cutera) | In-office 1726nm sebaceous-gland laser; FDA-cleared for mild–severe acne | Public parent (Cutera, NASDAQ) | Fast in-clinic sessions (30–45 min, no numbing); requires derm visit and capital equipment |
| Accure Laser | In-office 1726nm laser; 4-session protocol, ~70% acne reduction after series | Venture-backed | Deeper penetration; 2-hour sessions with nerve blocks — high friction vs. Indomo's at-home path |
| Hims & Hers Dermatology | Telehealth prescription acne (tretinoin, spironolactone, isotretinoin) | Public (NYSE: HIMS) | Massive consumer distribution but no injectable/device modality; potential channel partner given founder overlap |
Moat: Combination drug/device pathway plus a proprietary microneedle delivery form-factor creates a defensible, reimbursement-eligible product that no laser competitor can replicate at home.
Rick's 2024-03-07 recasting of Indomo as a drug/device life-sciences company (not a D2C aesthetics brand) put pharma dermatology as the natural exit surface. Precedent acquirers include Galderma, Almirall, Kenvue, and public dermatology-device platforms like Cutera. On StoryHouse's $200K basis at $25M post, a $500M pharma exit returns roughly $4M gross (~20x); a $1B outcome doubles that.
1 month out for feedback from FDA; this is most important next milestone.
Confirmed investment and advisorship from significant strategic advisor; Rick is focused on bringing on some individuals like this given the new clinical direction of the business in advance of the Series A.
Rick will follow-up for conversation with Matt now that they both are traveling less.
Summary: Let's see what FDA results are.
Had their third FDA update; Cedar wasn't willing to give them the pass on the drug side. They continue to support the device.
So they did a whole bunch of work on what that means; they're going to do a generic version of cortisone (Kenalog). Now they're looking at combination drug work. They will follow the same path on the device side, but have to do more work on the drug side.
But what it unlocks is that they can be completely reimbursable from payors — they'll reimburse them; $300M–$600M in annual spend. Anyone who is currently eligible for their medical benefits would be eligible for Dermatheory.
Same biz model and approach, but now they have a solid reimbursement option and has way more options for pharma exits. Biggest impact is on capital needs and timelines; now they look like a biotech drug company — to run Phase I and Phase II studies; they don't have to do this geographically limited launch.
GTM is highly de-risked. Biology risk is long gone, clinical risk is low, strong reimbursement mechanics. A lot of the heartburn that a lot of VCs had was judging the D2C framework; how do you actually get this paid for; they couldn't get their heads around that or the reimbursement side; didn't know how to deal with the regulatory risk. Now it puts them squarely in the life sciences.
Multiples in D2C crap right now. Previously it was all about post revenue; now they have options for post Phase II data with the combo product — that's prime for pharma M&A or investment; or post Phase III data; or post revenue. Timeline for Phase II: two years. Commercial clearance: four years.
Now they need to upsize this round. Kick off fundraising with pre-R&as submission. Might re-name.
Raise: Based on the clinical and payor feedback — next round will be $15–18M round or A2.
Runway: through December with the retool plan since they're no longer launching the product at the end of the year. Not looking for a bridge in the near term. Rick wants to close the round before July 4. This opens up pharma M&A as another option.
March 2023: 52 injections into the device trial (hit the first third of the cohort through); going to get the first read from physicians on how things are going. In general they're seeing similar clinical results as what they saw in the first trial; people are generally able.
Series A looks to be coming together. He's been building out the operational plan for commercialization. 8–9 months to get to commercialization; get early GTM metrics.
Looking at a $12M Series A; knock on a lot of wood, Polaris and Atomic are thinking about. He's pitching Polaris on April 24; he thinks they'll tranche; paper it close, then go out, say they have 8 committed on 12, here's the terms.
Because of the recruiting challenges, they didn't get the diversity of lesion types; positive data is always good, they're going to have a hard time optimizing future treatment opportunities. Now they're treating multiple lesions; more doses or higher concentration. That first trial went well.
In Rick's opinion, it's about as effective of a trial which could possibly be; the one thing that's going to remain open on the April time frame, is the 1.5% concentration rather. 8–9 gives them FDA clearance; 3–4 to launch; plan.
How do you want to acquire the 2.5K patients: two options — virtual presence with patients (traditional ecommerce marketing traction) or use in-office referrals at a select number of sites at specific geographies to utilize their funnel. He thinks they'll be one of the stars in that portfolio.
Speaking to Cara Davis who used to run Starface on the GTM side.